$TEVATEVA PHARMACEUTICAL INDUSTRIES LTD

📅 Upcoming

🕒 Recent(90d)

News

• Kolon TissueGene cuts 37 US staffers after Phase 3 fail
  Follow along as BioSpace tracks job cuts and restructuring initiatives.
  biospace · 18h ago
• Federal appeals court revives part of Teva's IRA case as Austedo price cuts loom
  After a lower court rejected Teva's case last fall, a federal appeals court has revived part of the drugmaker’s lawsuit against Medicare negotiations. The DC Circuit Court ruled on Tuesday that Tev…
  endpoints · 1d ago
• Slate uses Fulcrum to vault onto Nasdaq with $245M financing for migraine trials
  Slate Medicines is hurtling toward a Nasdaq listing, securing a reverse merger with Fulcrum Therapeutics six months after exiting stealth and ahead of the publication of clinical data on its lead c…
  fiercebiotech · 2d ago
• Lilly pens $370M deal with OmniAb for ion channel collab, but details remain vague
  Antibody platform business OmniAb continues to rack up Big Pharma partnerships, with Eli Lilly signing off on up to $370 million biobucks tied to an ion channel program.
  fiercebiotech · 3d ago
• Zealand sells its rights to Takeda’s blood cancer drug for $100M ahead of FDA approval decision
  As the FDA mulls whether to approve Takeda and Protagonist Therapeutics’ rusfertide, Zealand Pharma has sold its own rights to the blood cancer drug in return for $100 million.
  fiercebiotech · 7d ago
• Judge signs off on Teva's $35M settlement over delayed inhaler generics
  A Massachusetts federal judge on Wednesday approved a $35 million settlement between Teva Pharmaceuticals and a handful of healthcare funds over allegations the company delayed generic versions of…
  endpoints · 13d ago
• Attovia adds to biotech IPO momentum with $289M offering
  The startup is the 12th drug company to bank at least $250 million in an IPO this year, nearly matching totals last seen during the sector’s pandemic peak, according to BioPharma Dive data.
  biopharma_dive · 14d ago
• Merck’s $11B anti-TL1A bet delivers 1 win, 1 loss in midphase inflammatory disease trials
  A phase 2 trial of Merck & Co.’s anti-TL1A monoclonal antibody has missed its primary endpoint, closing off one avenue for expansion of an asset acquired in a $10.8 billion takeover. The setback wa…
  fiercebiotech · 16d ago
• Chutes & Ladders—Legend CEO departs without successor in place
  Legend Biotech CEO Ying Huang, Ph.D., has left the company suddenly, without a predecessor in place. Huang was elevated from CFO to CEO in 2020 after a Chinese customs investigation was opened on f…
  fiercebiotech · 20d ago
• Gerresheimer divests two businesses worth €1.5B; Resilience, Lilly boost injectable pen capacity
  Plus, news about Teva. 💶 Gerresheimer sells two subsidiaries to private equity: Gerresheimer is divesting its Centor and Primary Packaging Plastics (PPP) businesses to private equity firm Apax Par…
  endpoints · 20d ago